Homocysteine Lowering and Atherosclerosis Reduction Trial (HART)
Status:
Unknown status
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
Study Objective:
1. To evaluate whether combined therapy with folic acid 2.5 mg/day, vitamin B6 50 mg/day and
vitamin B12 1000 micrograms/day vs placebo reduces the rate of atherosclerosis progression,
as evaluated by quantitative B-mode carotid ultrasound (US).
Phase:
Phase 4
Details
Lead Sponsor:
Hamilton Health Sciences Corporation
Collaborators:
Canadian Institutes of Health Research (CIHR) Population Health Research Institute